FAP抗体;FAP Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using FAP mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using FAP mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using FAP mouse mAb with DAB staining.    

  
  

Fibroblast activation protein (FAP) is a type II transmembrane serine protease expressed predominantly by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Initially identified in the 1990s, FAP gained attention for its selective overexpression in stromal cells of epithelial-derived cancers, including pancreatic, breast, and colorectal carcinomas, as well as in fibrotic tissues. Unlike normal fibroblasts, CAFs promote tumor progression by remodeling the extracellular matrix, suppressing immune responses, and facilitating angiogenesis. FAP’s enzymatic activity contributes to these processes, making it a potential therapeutic target.

FAP antibodies are designed to either block its proteolytic function or deliver cytotoxic payloads to FAP-rich microenvironments. Preclinical studies demonstrate that FAP-targeting antibodies can inhibit tumor growth, enhance drug delivery, or modulate immune activity. However, clinical trials have shown mixed outcomes, partly due to FAP’s transient expression in wound healing and its presence in non-pathological tissues like adipocytes. Recent advancements focus on bispecific antibodies, antibody-drug conjugates (ADCs), or FAP-directed CAR-T cells to improve specificity and efficacy. Beyond oncology, FAP antibodies are explored in fibrosis and imaging applications, leveraging their ability to highlight stromal activity. Despite challenges, FAP remains a compelling biomarker and therapeutic candidate in stromal-rich diseases.